Related Experiment Video

Updated: May 26, 2026

Simple and Fast Rolling Circle Amplification-Based Detection of Topoisomerase 1 Activity in Crude Biological Samples
10:13

Simple and Fast Rolling Circle Amplification-Based Detection of Topoisomerase 1 Activity in Crude Biological Samples

Published on: December 2, 2022

Targeting DNA topoisomerase I with non-camptothecin poisons

G L Beretta1, V Zuco, P Perego

  • 1Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. giovanni.beretta@istitutotumori.mi.it

Current Medicinal Chemistry
|December 30, 2011
PubMed

Insights

New non-camptothecin DNA topoisomerase I inhibitors show promise as cancer therapeutics. This review evaluates preclinical data on these alternative agents, focusing on cellular pharmacology and clinical potential.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • DNA topoisomerase I is crucial for DNA relaxation in cellular processes.
  • Camptothecins are known DNA topoisomerase I inhibitors with clinical efficacy in cancer therapy.
  • Limitations of camptothecins, including poor solubility, stability, toxicity, and resistance, necessitate alternative treatments.

Purpose of the Study:

  • To comparatively evaluate preclinical results of non-camptothecin DNA topoisomerase I inhibitors.
  • To assess the cellular pharmacology of these novel agents.
  • To discuss the clinical perspectives of these alternative topoisomerase I inhibitors.

Main Methods:

  • Review and comparative analysis of preclinical data on various non-camptothecin topoisomerase I inhibitors.
  • Focus on studies examining cellular pharmacology and in vitro/in vivo efficacy.
  • Evaluation of resistance mechanisms and potential for clinical application.

Main Results:

  • Several classes of non-camptothecin compounds, including indolocarbazoles, dibenzonaphthyridines, and indenoisoquinolines, demonstrate significant potential as topoisomerase I inhibitors.
  • These agents exhibit promising preclinical efficacy and distinct pharmacological profiles.
  • Comparative analysis highlights specific advantages and challenges for different compound classes.

Conclusions:

  • Non-camptothecin topoisomerase I inhibitors represent a promising alternative for cancer therapy, overcoming limitations of existing drugs.
  • Further preclinical and clinical investigation is warranted to optimize their therapeutic use.
  • These agents offer a valuable avenue for developing novel anticancer strategies targeting DNA topoisomerase I.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Quantitative Detection of DNA-Protein Crosslinks and Their Post-Translational Modifications10:12

Quantitative Detection of DNA-Protein Crosslinks and Their Post-Translational Modifications

Published on: April 21, 2023

Related Concept Videos

DNA Topoisomerases02:02

DNA Topoisomerases

Topoisomerases are enzymes that relax overwound DNA molecules during various cell processes, including DNA replication and transcription. These enzymes regulate positive and negative DNA supercoiling without changing the nucleotide sequence. DNA overwinding in a clockwise direction results in positively supercoiled DNA, whereas underwinding in a counterclockwise direction produces negatively supercoiled DNA.
Types and Mechanism of action
Topoisomerases are divided into two main types.  Type I...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...